Form 4: Corcept CFO Mokari Buys Shares, Receives Awards

Corcept Therapeutics CFO Atabak Mokari increased his direct beneficial ownership through a purchase plan and restricted stock awards, while also disposing of shares for tax obligations.

Summary

• Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc. (CORT), acquired 397 shares of common stock at $35.97 per share on March 2, 2026, through a company purchase plan.
• Mokari also received 397 shares underlying unvested restricted stock awards under the same purchase plan on March 2, 2026, with a price of $0.00.
• On March 3, 2026, 96 shares were disposed of at $35.97 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Mokari beneficially owns 15,257 shares directly.
• The beneficial ownership includes 232 shares from March 3, 2025, 775 shares from June 2, 2025, 200 shares from September 2, 2025, and 178 shares from December 1, 2025, all underlying unvested restricted stock awards.
• 100% of the shares underlying these restricted stock awards will vest on the one-year anniversary of their respective grant dates, subject to certain requirements.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing due to the CFO's direct stock purchase and the receipt of long-term restricted stock awards, which collectively signal strong insider confidence despite a routine tax-related share disposition.

Positives

• Chief Financial Officer Atabak Mokari directly purchased 397 shares of common stock, signaling confidence in the company's future.
• The acquisition of 397 shares as unvested restricted stock awards under a purchase plan aligns management's interests with long-term shareholder value.
• A significant portion of the beneficial ownership (1,385 shares from previous grants, plus the new 397 shares) is tied to unvested restricted stock awards, promoting long-term retention and performance.

Negatives

• 96 shares were disposed of to cover tax withholding obligations, representing a reduction in direct ownership, although this is a common practice for equity compensation.

Future Outlook

100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of their respective grant dates, provided the Reporting Person satisfies certain requirements or remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. This indicates a long-term incentive structure for the CFO.

Industry Context

StockSavvy.ai notes that insider buying, particularly by a Chief Financial Officer, often signals management's confidence in the company's financial health and future prospects. In the biotechnology and pharmaceutical sectors, such signals can be particularly impactful given the inherent risks and long development cycles, suggesting a positive internal outlook for Corcept Therapeutics.

Stakeholder Impact

• Shareholders may view the CFO's direct stock purchase as a positive indicator of management's belief in the company's value, potentially increasing investor confidence.
• The long-term vesting schedule for restricted stock awards incentivizes management to focus on sustained company performance, benefiting long-term shareholders.

Next Steps

• The vesting of 232 restricted stock awards on March 3, 2026 (one-year anniversary of grant).
• The vesting of 775 restricted stock awards on June 2, 2026 (one-year anniversary of grant).
• The vesting of 200 restricted stock awards on September 2, 2026 (one-year anniversary of grant).
• The vesting of 178 restricted stock awards on December 1, 2026 (one-year anniversary of grant).
• The vesting of 397 restricted stock awards on March 2, 2027 (one-year anniversary of grant), contingent on the Reporting Person remaining the beneficial owner of the Purchase Plan Shares.

Key Dates

Recommendation

The direct purchase of company stock by the Chief Financial Officer, coupled with the receipt of additional long-term restricted stock awards, indicates strong insider confidence in Corcept Therapeutics' future prospects and valuation. This insider buying activity is a positive signal for investors, suggesting potential upside and aligning management's interests with shareholder returns.

Keywords

Corcept Therapeutics, CORT, Atabak Mokari, Insider Trading, Form 4, Stock Purchase Plan, Restricted Stock Awards, Beneficial Ownership, CFO, Biotechnology, Pharmaceuticals